ヨーロッパのアシネトバクター肺炎治療薬市場は、2023年に約6,016万米ドルと評価され、2024年から2032年の予測期間にわたって5.80%を超える健全な成長率で成長すると予想されています。
アシネトバクター肺炎治療薬には、さまざまな抗生物質に対する耐性で悪名高いグラム陰性細菌であるアシネトバクター・バウマニによって引き起こされる肺炎に対処することを目的とした薬理学的介入と治療戦略が含まれます。通常、治療には、特定の菌株の感受性パターンに合わせて調整された抗菌剤の混合が含まれ、関連する合併症を管理するための支持措置が補完されます。ヨーロッパのアシネトバクター肺炎治療薬市場は、薬剤耐性感染症と院内肺炎の症例の増加に後押しされて、着実な成長を示しています。継続的な研究努力は、この分野でカスタマイズされた医薬品を進歩させ、患者の転帰を向上させる上で重要な役割を果たします。
肺炎の有病率の上昇は、特に高齢者や免疫不全者の間で、有効な治療法の需要を促進しています。さらに、ヨーロッパの製薬会社、学術機関、研究機関は、アシネトバクター肺炎の新しい薬や治療法を発見するための研究開発に積極的に取り組んでいます。このイノベーションへの投資は、新しい治療オプションを導入することで市場の成長を促進すると予想されています。さらに、ヨーロッパのアシネトバクター肺炎治療薬市場は、アシネトバクター感染症の発生率の増加と、ヘルスケア業界に対する政府の支援策と資金提供によって推進されています。限られた抗生物質の選択肢の中で、ペプチドやナノ粒子などの代替戦略が重要であり、抗菌薬耐性に対するイノベーションの必要性を浮き彫りにし、ヨーロッパのアシネトバクター肺炎治療薬市場に課題をもたらしています。
ヨーロッパのアシネトバクター肺炎治療薬市場調査の対象となる主要国には、イギリス、ドイツ、フランス、イタリア、スペイン、その他のヨーロッパ諸国が含まれます。イギリスは2023年に最も急速に成長した地域であり、着実な成長は薬剤耐性感染症と院内肺炎の増加によって推進されており、主な推進要因には診断の進歩と効果的な治療法の需要が含まれます。フランスの市場成長は、感染症の増加、毒性因子と耐性に関する研究、治療結果を改善するための新しい抗菌薬の探索に起因しています。一方、ドイツでは最も急速な成長が予測されています。
目次
Table of Contents
Chapter 1. Europe Acinetobacter Pneumonia Therapeutics Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
Chapter 2. Executive Summary
2.1. Europe Acinetobacter Pneumonia Therapeutics Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Drug Class
2.3.2. By Route of Administration
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe Acinetobacter Pneumonia Therapeutics Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe Acinetobacter Pneumonia Therapeutics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe Acinetobacter Pneumonia Therapeutics Market Size & Forecasts by Drug Class 2022-2032
5.1. Cephalosporins
5.2. Fluoroquinolone
5.3. Glycylcycline
5.4. Carbapenem
5.5. β-Lactam antibiotics
5.6. Sulbactam
5.7. Aminoglycoside
5.8. Polymyxins
5.9. Tetracycline
5.10. Sulfonamide
5.11. Others
Chapter 6. Europe Acinetobacter Pneumonia Therapeutics Market Size & Forecasts by Route of Administration 2022-2032
6.1. Parental
6.2. Oral
6.3. Others
Chapter 7. Europe Acinetobacter Pneumonia Therapeutics Market Size & Forecasts by Country 2022-2032
7.1. U.K. Acinetobacter Pneumonia Therapeutics Market
7.1.1. Drug Class breakdown size & forecasts, 2022-2032
7.1.2. Route of Administration breakdown size & forecasts, 2022-2032
7.2. Germany Acinetobacter Pneumonia Therapeutics Market
7.3. France Acinetobacter Pneumonia Therapeutics Market
7.4. Spain Acinetobacter Pneumonia Therapeutics Market
7.5. Italy Acinetobacter Pneumonia Therapeutics Market
7.6. Rest of Europe Acinetobacter Pneumonia Therapeutics Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. GlaxoSmithKline Plc (GSK)
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. AstraZeneca Plc
8.3.3. Novartis AG
8.3.4. Sanofi S.A.
8.3.5. Bayer AG
8.3.6. Basilea Pharmaceutical Ltd.
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
List of Tables
TABLE 1. Europe Acinetobacter Pneumonia Therapeutics market, report scope
TABLE 2. Europe Acinetobacter Pneumonia Therapeutics market estimates & forecasts by Country 2022-2032 (USD Million)
TABLE 3. Europe Acinetobacter Pneumonia Therapeutics market estimates & forecasts by Drug Class 2022-2032 (USD Million)
TABLE 4. Europe Acinetobacter Pneumonia Therapeutics market estimates & forecasts by Route of Administration 2022-2032 (USD Million)
TABLE 5. Europe Acinetobacter Pneumonia Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 6. Europe Acinetobacter Pneumonia Therapeutics market by country, estimates & forecasts, 2022-2032 (USD Million)
TABLE 7. Europe Acinetobacter Pneumonia Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. Europe Acinetobacter Pneumonia Therapeutics market by country, estimates & forecasts, 2022-2032 (USD Million)
TABLE 9. Europe Acinetobacter Pneumonia Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 10. Europe Acinetobacter Pneumonia Therapeutics market by country, estimates & forecasts, 2022-2032 (USD Million)
TABLE 11. Europe Acinetobacter Pneumonia Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 12. Europe Acinetobacter Pneumonia Therapeutics market by country, estimates & forecasts, 2022-2032 (USD Million)
TABLE 13. Europe Acinetobacter Pneumonia Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Million) Europe Acinetobacter Pneumonia Therapeutics market by country, estimates & forecasts, 2022-2032 (USD Million)
TABLE 14. UK Acinetobacter Pneumonia Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 15. UK Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 16. UK Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 17. Germany Acinetobacter Pneumonia Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 18. Germany Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 19. Germany Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 20. France Acinetobacter Pneumonia Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 21. France Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 22. France Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 23. Italy Acinetobacter Pneumonia Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 24. Italy Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 25. Italy Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 26. Spain Acinetobacter Pneumonia Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 27. Spain Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 28. Spain Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 29. RoE Acinetobacter Pneumonia Therapeutics market estimates & forecasts, 2022-2032 (USD Million)
TABLE 30. RoE Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 31. RoE Acinetobacter Pneumonia Therapeutics market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 32. List of secondary sources, used in the study of Europe Acinetobacter Pneumonia Therapeutics Market.
TABLE 33. List of primary sources, used in the study of Europe Acinetobacter Pneumonia Therapeutics Market.
TABLE 34. Years considered for the study.
TABLE 35. Exchange rates considered.
List of figures
FIG 1. Europe Acinetobacter Pneumonia Therapeutics market, research methodology
FIG 2. Europe Acinetobacter Pneumonia Therapeutics market, market estimation techniques
FIG 3. Europe market size estimates & forecast methods.
FIG 4. Europe Acinetobacter Pneumonia Therapeutics market, key trends 2023
FIG 5. Europe Acinetobacter Pneumonia Therapeutics market, growth prospects 2022-2032
FIG 6. Europe Acinetobacter Pneumonia Therapeutics market, porters 5 force model
FIG 7. Europe Acinetobacter Pneumonia Therapeutics market, pestel analysis
FIG 8. Europe Acinetobacter Pneumonia Therapeutics market, value chain analysis
FIG 9. Europe Acinetobacter Pneumonia Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 10. Europe Acinetobacter Pneumonia Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 11. Europe Acinetobacter Pneumonia Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 12. Europe Acinetobacter Pneumonia Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 13. Europe Acinetobacter Pneumonia Therapeutics market by segment, 2022 & 2032 (USD Million)
FIG 14. Europe Acinetobacter Pneumonia Therapeutics market, Country snapshot 2022 & 2032
FIG 15. Europe Acinetobacter Pneumonia Therapeutics market 2022 & 2032 (USD Million)
FIG 16. Europe Acinetobacter Pneumonia Therapeutics market, company market share analysis (2023)
